Of note, BCL-2 protein levels better predict the sensitivity of neuroblastoma cell lines to ABT199 than BCL-2 mRNA levels, as shown by the factor difference in average expression between the sensitive and insensitive cell lines (i.e. ∼14 versus ∼4). The gene discussed is BCL2; the disease is neuroblastoma.